[1] Verhoeven NM, Huck JH, Roos B, et al. Transaldolase deficiency: liver cirrhosis associated with a new inborn error in the pentose phosphate pathway. Am J Hum Genet,2001,68: 1086-1092.
[2] Eyaid W, Al HT, Anazi S, et al. Transaldolase deficiency: report of 12 new cases and further delineation of the phenotype. J Inherit Metab Dis,2013, 36: 997-1004.
[3] Leduc CA, Crouch EE, Wilson A, et al. Novel association of early onset hepatocellular carcinoma with transaldolase deficienc. JIMD Rep. 2014,12: 121-127.
[4] Wamelink MM, Struys EA, Salomons GS,et al. Transaldolase deficiency in a two-year-old boy with cirrhosis. Mol Genet Metab. 2008,94: 255-258.
[5] Al-Shamsi AM, Ben-Salem S, Hertecant J, et al. Transaldolase deficiency caused by the homozygous p.R192C mutation of the TALDO1 gene in four Emirati patients with considerable phenotypic variability. Eur J Pediatr. 2015,17: 661-668.
[6] Balasubramaniam S, Wamelink MM, Ngu LH, et al. Novel heterozygous mutations in TALDO1 gene causing transaldolase deficiency and early infantile liver failure. J Pediatr Gastroenterol Nutr. 2011,52: 113-116.
[7] Banne E, Meiner V, Shaag A, et al. Transaldolase deficiency: a new case expands the phenotypic spectrum. JIMD Rep. 2016,26: 31-36.
[8] Tylki-Szymanska A, Wamelink MM, Stradomska TJ, et al. Clinical and molecular characteristics of two transaldolase-deficient patients. Eur J Pediatr. 2014,173: 1679-1682.
[9] A_newVerhoeven NM, Wallot M, Huck JH, et al. A newborn with severe liver failure, cardiomyopathy and transaldolase deficiency. J Inherit Metab Dis. 2005,28: 169-179 .
[10] Valayannopoulos V, Verhoeven NM, Mention K, et al. Transaldolase deficiency: a new cause of hydrops fetalis and neonatal multi-organ disease. J Pediatr. 2006,149: 713-717.
[11] Tylki-Szymańska A, Stradomska TJ, Wamelink MM, et al. Transaldolase deficiency in two new patients with a relative mild phenotype. Mol Genet Metab. 2009,97: 15-17.
[12] Jassim N, Alghaihab M, Saleh SA, et al. Pulmonary manifestations in a patient with transaldolase deficiency. JIMD Rep, 2014,12:47-50.
[13] Engelke UF, Zijlstra FS, Mochel F, et al. Mitochondrial involvement and erythronic acid as a novel biomarker in transaldolase deficiency. Biochim Biophys Acta. 2010,1802: 1028-1035 .
[14] Perl A, Hanczko R, Telarico T, et al. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med, 2011,17:395-403.
[15] Kowalik MA, Columbano A, Perra A. Emerging Role of the Pentose Phosphate Pathway in Hepatocellular Carcinoma. Front Oncol, 2017,7:87.
[16] González-Rodríguez I, Sánchez B, Ruiz L, et al. Role of extracellular transaldolase from Bifidobacterium bifidum in mucin adhesion and aggregation. Appl Environ Microbiol, 2012,78:3992-3998.
[17] Liu JY, Li SD, Sun MH. Transaldolase gene Tal67 enhances the biocontrol activity of Clonostachys rosea 67-1 against Sclerotinia sclerotiorum. Biochem Biophys Res Commun, 2016,474:503-508.
[18] ALight SH, Minasov G, Duban ME, et al. Adherence to Bürgi-Dunitz stereochemical principles requires significant structural rearrangements in Schiff-base formation: insights from transaldolase complexes. Acta Crystallogr D Biol Crystallogr, 2014,70:544-552.
[19] Huang SY, Zhang YH, Zhong JJ. A thermostable recombinant transaldolase with high activity over a broad pH range. Appl Microbiol Biotechnol, 2012,93:2403-2410.
[20] Moriyama T, Tanaka S, Nakayama Y, et al. Two isoforms of TALDO1 generated by alternative translational initiation show differential nucleocytoplasmic distribution to regulate the global metabolic network. Sci Rep, 2016,6:34648.
[21] Qian Y, Banerjee S, Grossman CE, et al. Transaldolase deficiency influences the pentose phosphate pathway, mitochondrial homoeostasis and apoptosis signal processing. Biochem J, 2008,415:123-134.
[22] Wamelink MM, Struys EA, Valayannopoulos V, et al. Retrospective detection of transaldolase deficiency in amniotic fluid: implications for prenatal diagnosis. Prenat Diagn, 2008,28:460-462.
[23] Hanczko R, Fernandez DR, Doherty E, et al. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. J Clin Invest, 2009,119:1546-1557.
[24] Loeffen YG, Biebuyck N, Wamelink MM, et al. Nephrological abnormalities in patients with transaldolase deficiency. Nephrol Dial Transplant. 2012. 27: 3224-3227.
[25] Wartofsky L. Combination L-T3 and L-T4 therapy for hypothyroidism. Curr Opin Endocrinol Diabetes Obes, 2013,20:460-466.
[26] GeneReviews○R. Seattle (WA):University of Washington, Seattle,1993.
[27] Bodaghkhan F, Geramizadeh B, Rajeh AA, et al. A Rapid Screening Test on Dried Blood for the Neonatal Diagnosis of Tyrosinemia Type I. Iran J Pediatr, 2016,26:e4624.
[28] de Laet C, Dionisi-Vici C, Leonard JV, et al. Recommendations for the management of tyrosinaemia type 1. Orphanet J Rare Dis, 2013,8:8.
[29] 韩连书, 叶军, 邱文娟, 等. 血尿琥珀酰丙酮检测在酪氨酸血症-Ⅰ型诊断中的应用.中华儿科杂志,2012,50:126-130.
[30] Dweikat IM, Alawneh IS, Bahar SF, et al. Fanconi-Bickel syndrome in two Palestinian children: marked phenotypic variability with identical mutation. BMC Res Notes, 2016,9:387.
[31] Pogoriler J, O′Neill AF, Voss SD, et al. Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. Pediatr Dev Pathol, 2017.
[32] Bahíllo-Curieses MP, Garrote-Molpeceres R, Miambres-Rodríguez M,et al. Glycosuria and hyperglycemia in the neonatal period as the first clinical sign of Fanconi-Bickel syndrome. Pediatr Diabetes, 2017.
[33] Durand P, Debray D, Mandel R, et al. Acute liver failure in infancy: a 14-year experience of a pediatric liver transplantation center. J Pediatr, 2001,139:871-876.
[34] Tsai A, Paltiel HJ, Sena LM, et al. Neonatal hemochromatosis and patent ductus venosus: clinical course and diagnostic pitfalls. Pediatr Radiol, 2009,39:823-827.
[35] Bonilla S, Prozialeck JD, Malladi P, et al. Neonatal iron overload and tissue siderosis due to gestational alloimmune liver disease. J Hepatol, 2012,56:1351-1355.
[36] Ludwig M, Levtchenko E, Bkenkamp A. Clinical utility gene card for: Dent disease (Dent-1 and Dent-2). Eur J Hum Genet, 2014,22.
[37] 李国民, 方晓燕, 徐虹, 等. 儿童2型Dent病1例并文献复习.中国循证儿科杂志,2014,6:456-459.
[38] 简珊, 魏珉, 何艳燕, 等. Dent病4例临床及基因分析.中国当代儿科杂志,2015,12:1261-1266.
[39] Song E, Luo N, Alvarado JA, et al. Ocular pathology of oculocerebrorenal syndrome of lowe: novel mutations and genotype-phenotype analysis. Sci Rep, 2017,7:1442.
[40] Warner BE, Inward CD, Burren CP. Gonadotrophin abnormalities in an infant with Lowe syndrome. Endocrinol Diabetes Metab Case Rep, 2017.
[41] 史瑞明, 卞旭华, 李立敏, 等. 眼脑肾综合征一家系调查及OCRL基因突变分析.中国当代儿科杂志,2014,4:366-369.
[42] Rodan LH, Berry GT. N-Acetylcysteine therapy in an infant with transaldolase deficiency is well tolerated and associated with normalization of alpha fetoprotein levels. JIMD Rep, 2017,31:73-77. |
